After 6 years of delivering practice management tools and solutions for veterinary teams, veterinaryteambrief.com closed at the end of 2018. Veterinary Team Brief archived content and Social Media Calendars are accessible on cliniciansbrief.com. For more information about accessing Veterinary Team Brief content, click here.

Desoxycorticosterone Pivalate (DOCP)

November / December 2018

Sign in to Print/View PDF

Desoxycorticosterone Pivalate (DOCP)

Mineralocorticoid (Systemic Drug)

Prescriber Highlights

  • Parenteral mineralocorticoid used to treat hypoadrenocorticism (ie, Addison’s disease)
  • Does not contain any glucocorticoid activity; a glucocorticoid must be used concurrently in the treatment of Addison’s disease
  • Adjust dosage based on monitoring parameters
Uses, Indications
  • Indicated for the parenteral treatment of adrenocortical insufficiency (ie, Addison’s disease) in dogs
  • Used extra-label for the same indication in cats
Contraindications, Precautions, Warnings
  • Contraindications
    • Patients with hypersensitivity to DOCP, congestive heart failure, severe renal disease, primary hepatic failure, or edema
  • Precautions
    • Some animals may be more or less sensitive to the drug’s effects; dosing without ongoing monitoring is inappropriate
    • Do not administer intravenously as acute collapse and shock may result
  • Warnings
    • Animals suffering from hypovolemia, prerenal azotemia, and inadequate tissue perfusion must be rehydrated with intravenous fluid therapy before starting DOCP
Side Effects
  • Possible irritation at the injection site
  • Depression, lethargy, vomiting, anorexia, polydipsia, polyuria, panting, diarrhea, facial and muzzle edema, urticaria, anaphylaxis, urinary tract infection, urinary incontinence, restlessness
  • Anemia following injection has been reported
Drug Interactions
  • Concurrent use with amphotericin B or potassium-depleting diuretics may result in hypokalemia
  • Potassium-sparing diuretics may counter the DOCP effects
  • May reduce salicylate levels when used with aspirin
  • Use in diabetic patients may result in increased insulin requirement
Monitoring
  • Serum electrolytes, BUN, creatinine
  • Body weight, physical examination, evidence of edema
Client Information
  • Most commonly injected into the muscle, but can be given subcutaneously
    • Must never be given intravenously
  • Shake the vial vigorously before drawing up into the syringe
  • Monitor for symptoms of the dose being too high (eg, increased thirst and urination, edema, weight gain) or too low (eg, lethargy, collapse, inappetence, weakness, vomiting, diarrhea)
Dosage Forms
  • Desoxycorticosterone pivalate injectable suspension:
    • 25 mg/ml

Compiled and summarized from Plumb’s® Veterinary Drugs by Shannon Palermo, VMD

Information about this drug was adapted from Plumb’s® Veterinary Drugs. Further details and more therapeutics can be found with a subscription at plumbsveterinarydrugs.com

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Practice Tools

Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)